377 related articles for article (PubMed ID: 29384959)
1. Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population.
Chen WC; Chu PY; Lee YT; Lu WB; Liu CY; Chang PM; Yang MH
Medicine (Baltimore); 2017 Dec; 96(52):e9519. PubMed ID: 29384959
[TBL] [Abstract][Full Text] [Related]
2. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.
Sheth S; Weiss J
Future Oncol; 2018 Jul; 14(16):1547-1558. PubMed ID: 29464975
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
[TBL] [Abstract][Full Text] [Related]
5. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
[TBL] [Abstract][Full Text] [Related]
6. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Saâda-Bouzid E; Defaucheux C; Karabajakian A; Coloma VP; Servois V; Paoletti X; Even C; Fayette J; Guigay J; Loirat D; Peyrade F; Alt M; Gal J; Le Tourneau C
Ann Oncol; 2017 Jul; 28(7):1605-1611. PubMed ID: 28419181
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012.
Tahara M; Muro K; Hasegawa Y; Chung HC; Lin CC; Keam B; Takahashi K; Cheng JD; Bang YJ
Cancer Sci; 2018 Mar; 109(3):771-776. PubMed ID: 29284202
[TBL] [Abstract][Full Text] [Related]
8. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
9. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab.
Acero Brand FZ; Suter N; Adam JP; Faulques B; Maietta A; Soulières D; Blais N
J Immunother Cancer; 2018 Mar; 6(1):22. PubMed ID: 29548299
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
[TBL] [Abstract][Full Text] [Related]
11. Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer.
Chen TH; Chang PM; Yang MH
J Chin Med Assoc; 2021 Apr; 84(4):361-367. PubMed ID: 33496513
[TBL] [Abstract][Full Text] [Related]
12. Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma.
Desilets A; Soulières D
Expert Opin Drug Saf; 2020 Aug; 19(8):927-934. PubMed ID: 32458764
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
Saada-Bouzid E; Peyrade F; Guigay J
Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
[TBL] [Abstract][Full Text] [Related]
15. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
Ott PA; Piha-Paul SA; Munster P; Pishvaian MJ; van Brummelen EMJ; Cohen RB; Gomez-Roca C; Ejadi S; Stein M; Chan E; Simonelli M; Morosky A; Saraf S; Emancipator K; Koshiji M; Bennouna J
Ann Oncol; 2017 May; 28(5):1036-1041. PubMed ID: 28453692
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Lang Y; Dong D; Wu B
Clin Drug Investig; 2020 Dec; 40(12):1137-1146. PubMed ID: 33095408
[TBL] [Abstract][Full Text] [Related]
17. Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System.
Liu Y; Fitzgerald B; Perry E; Pathak A; Chao HH
J Investig Med High Impact Case Rep; 2019; 7():2324709619850216. PubMed ID: 31132886
[TBL] [Abstract][Full Text] [Related]
18. Exceptional Response to PD-1 Blockade as First-Line Therapy in Head and Neck Squamous Cell Carcinoma.
Kumai T; Komatsuda H; Minami Y; Harabuchi Y
ORL J Otorhinolaryngol Relat Spec; 2020; 82(6):343-350. PubMed ID: 32882699
[TBL] [Abstract][Full Text] [Related]
19. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
20. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.
Aggarwal C; Prawira A; Antonia S; Rahma O; Tolcher A; Cohen RB; Lou Y; Hauke R; Vogelzang N; P Zandberg D; Kalebasty AR; Atkinson V; Adjei AA; Seetharam M; Birnbaum A; Weickhardt A; Ganju V; Joshua AM; Cavallo R; Peng L; Zhang X; Kaul S; Baughman J; Bonvini E; Moore PA; Goldberg SM; Arnaldez FI; Ferris RL; Lakhani NJ
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35414591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
